title: Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures.
abstract: This study was designed to compare the clinical and bacteriological efficacy of three oral cephalosporins, cefuroxime axetil, cephalexin and cefadroxil, in the treatment of patients with mild to moderate infections of the skin or skin structures. A total of 330 patients were enrolled at 10 centers and were randomly assigned to receive cefuroxime axetil 250 mg (n = 107), cephalexin 500 mg (n = 111) or cefadroxil 500 mg (n = 112), twice daily for 10 days. Patients were assessed for their clinical and bacteriological responses once during treatment (3-5 days) and twice after treatment (1-3 and 10-14 days). A total of 353 bacterial isolates were obtained: Staphylococcus aureus (41%), Staphylococcus epidermidis (33%) and Streptococcus pyogenes (5%). A satisfactory clinical outcome (cure or improvement) was achieved in 97% (89/92), 89% (80/90) and 94% (82/87) of the clinically evaluable patients treated with cefuroxime axetil, cephalexin or cefadroxil, respectively (p = 0.047, cefuroxime axetil vs. cephalexin). With respect to the eradication of the bacterial pathogens, a satisfactory outcome (cure or presumed cure) was obtained in 96% (69/72), 85% (60/71) and 93% (63/68) of bacteriologically evaluable patients treated with cefuroxime axetil, cephalexin and cefadroxil, respectively (p = 0.026, cefuroxime axetil vs. cephalexin). All three study drugs were well tolerated, with adverse events affecting the gastrointestinal system most commonly reported. There were no significant differences between treatment groups in the incidence of drug-related adverse events.
authors.affiliation: Primary Children's Hospital, Salt Lake City, Utah.
authors.forename: W M
authors.initials: WM
authors.lastname: Gooch
authors.forename: L
authors.initials: L
authors.lastname: Kaminester
authors.forename: G W
authors.initials: GW
authors.lastname: Cole
authors.forename: R
authors.initials: R
authors.lastname: Binder
authors.forename: M R
authors.initials: MR
authors.lastname: Morman
authors.forename: J M
authors.initials: JM
authors.lastname: Swinehart
authors.forename: M
authors.initials: M
authors.lastname: Wisniewski
authors.forename: H M
authors.initials: HM
authors.lastname: Yilmaz
authors.forename: J J
authors.initials: JJ
authors.lastname: Collins
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002434:Cefadroxil / Q000009:adverse effects / Q000627:therapeutic use; D002444:Cefuroxime / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002506:Cephalexin / Q000009:adverse effects / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000627:therapeutic use; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D002511:Cephalosporins; D011355:Prodrugs; D002434:Cefadroxil; D002444:Cefuroxime; D002506:Cephalexin; C040738:cefuroxime axetil